ERBB2 and breast cancer: Furthermore, truncated p95HER2 has been shown to have a peculiar structure, and both preclinical [47] and clinical investigations in the metastatic HER2+ BC setting have provided evidence that CTFs are relevant biomarkers of trastuzumab therapy resistance [47,70].